Raras
Buscar doenças, sintomas, genes...
Oligoastrocitoma
ORPHA:251656CID-10 · C71.9CID-11 · 2A00.0YDOENÇA RARA

Tumor grau II da OMS composto por uma mistura notável de dois tipos distintos de células neoplásicas que se assemelham morfologicamente às células tumorais do oligodendroglioma e do astrocitoma difuso. (QUEM)

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Tumor grau II da OMS composto por uma mistura notável de dois tipos distintos de células neoplásicas que se assemelham morfologicamente às células tumorais do oligodendroglioma e do astrocitoma difuso. (QUEM)

Pesquisas ativas
6 ensaios
91 total registrados no ClinicalTrials.gov
Publicações científicas
610 artigos
Último publicado: 2026 Apr
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: C71.9
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2025
Total histórico610PubMed
Últimos 10 anos189publicações
Pico201542 papers
Linha do tempo
2025Hoje · 2026🧪 1994Primeiro ensaio clínico📈 2015Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição.

IDH2Isocitrate dehydrogenase [NADP], mitochondrialBiomarker tested inAltamente restrito
FUNÇÃO

Plays a role in intermediary metabolism and energy production (PubMed:19228619, PubMed:22416140). It may tightly associate or interact with the pyruvate dehydrogenase complex (PubMed:19228619, PubMed:22416140)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (4)
Citric acid cycle (TCA cycle)Maturation of TCA enzymes and regulation of TCA cycleMitochondrial protein degradationTranscriptional activation of mitochondrial biogenesis
MECANISMO DE DOENÇA

D-2-hydroxyglutaric aciduria 2

A neurometabolic disorder causing developmental delay, epilepsy, hypotonia, and dysmorphic features. Both a mild and a severe phenotype exist. The severe phenotype is homogeneous and is characterized by early infantile-onset epileptic encephalopathy and cardiomyopathy. The mild phenotype has a more variable clinical presentation. Diagnosis is based on the presence of an excess of D-2-hydroxyglutaric acid in the urine.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
442.8 TPM
Coração - Ventrículo esquerdo
311.5 TPM
Rim - Medula
273.8 TPM
Linfócitos
186.0 TPM
Fígado
184.7 TPM
OUTRAS DOENÇAS (13)
d-2-hydroxyglutaric aciduria 2anaplastic oligodendrogliomagemistocytic astrocytomaoligoastrocytoma
HGNC:5383UniProt:P48735

Variantes genéticas (ClinVar)

82 variantes patogênicas registradas no ClinVar.

🧬 IDH2: GRCh38/hg38 15q26.1-26.3(chr15:90068508-101888837)x3 ()
🧬 IDH2: NM_002168.4(IDH2):c.800A>G (p.Gln267Arg) ()
🧬 IDH2: GRCh37/hg19 15q26.1-26.3(chr15:90569376-102369410)x1 ()
🧬 IDH2: NM_002168.4(IDH2):c.448G>C (p.Glu150Gln) ()
🧬 IDH2: NM_002168.4(IDH2):c.1081-60C>G ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
2Fase 28
1Fase 110
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Oligoastrocitoma

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

91 ensaios clínicos encontrados, 6 ativos.

Distribuição por fase
NCT03152318 · A Study of the Treatment of Recurrent Malignant Glioma With …Ativo
PHASE1
NCT07031765 · Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antib…Ativo
PHASE1
NCT02192359 · Carboxylesterase-Expressing Allogeneic Neural Stem Cells and…Ativo
PHASE1
NCT03180502 · Proton Beam or Intensity-Modulated Radiation Therapy in Pres…Ativo
PHASE2
NCT01849952 · Evaluating the Expression Levels of MicroRNA-10b in Patients…Encerrado
NCT02026271 · A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Gli…Concluído
PHASE1
NCT02549833 · Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Gra…Concluído
PHASE1
NCT02530320 · Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dep…Concluído
PHASE2
NCT02372409 · Using MRI-Guided Laser Heat Ablation to Induce Disruption of…Encerrado
PHASE2
NCT02924038 · A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in P…Encerrado
PHASE1
NCT03043391 · Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Chi…Concluído
PHASE1
NCT01922076 · Adavosertib and Local Radiation Therapy in Treating Children…Concluído
PHASE1
NCT02168270 · Temozolomide and Ascorbic Acid in Treating Patients With Rec…Encerrado
PHASE1
NCT01721577 · Phase I/II Trial of AXL1717 in the Treatment of Recurrent Ma…Encerrado
PHASE1, PHASE2
NCT03072134 · Neural Stem Cell Based Virotherapy of Newly Diagnosed Malign…Concluído
PHASE1
NCT05600491 · A Phase III Study of Postoperative Early Temozolomide Treatm…UNKNOWN
PHASE3
NCT00303849 · Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and S…Concluído
PHASE1, PHASE2
NCT01189266 · Vorinostat and Radiation Therapy Followed by Maintenance The…Concluído
PHASE1, PHASE2
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
189 papers (10 anos)
#1

Endoscopic Transorbital Approach for Select Recurrent and Newly Diagnosed Anteromedial Temporal Lobe Gliomas.

Journal of neurological surgery. Part B, Skull base2026 Apr

The endoscopic lateral transorbital approach (eLTOA) has emerged as a minimal access technique for accessing the middle fossa and periorbital region. This study explores the applicability of eLTOA in the management of recurrent and newly diagnosed medial temporal lobe gliomas. Forty patients at our institution underwent eLTOA between 2016 and 2024. There were five surgeries for glioma. Patients were assessed for demographic and clinical data, radiographic characteristics, and histopathological and molecular findings. Four recurrent gliomas required biopsy for diagnosis and molecular genotyping, and one newly diagnosed tumor aimed for gross total resection (GTR). Histologic diagnoses remained unchanged in three recurrent cases (two glioblastoma multiforme and one xanthoastrocytoma). One case was upgraded from oligoastrocytoma Grade II to glioblastoma Grade IV. GTR was achieved in the newly diagnosed tumor, with histology confirming dysembryoplastic neuroepithelial tumor. Average length of stay was 3 days. There was one case of transient diplopia. eLTOA offers a minimally invasive, direct approach to medial temporal lobe gliomas that minimizes the risks of infection and temporalis muscle atrophy associated with reoperation through a previously irradiated incision. It is most useful for restaging recurrent tumors, although GTR can be obtained in well-selected newly diagnosed tumors.

#2

Risk factors for postoperative malignant progression of lower-grade gliomas: a systematic review and meta-analysis.

Surgical oncology2026 Feb

The primary aim was to evaluate the risk factors for postoperative malignant progression of lower-grade glioma (LGG) in patients. PubMed, EMBASE, Web of Science and Cochrane Library were searched from database inception to August 2024. Quantitative and original studies reporting risk factors for postoperative malignant progression of LGGs were included. 17 observational studies with 3810 glioma patients met the inclusion criteria. Factors including advanced age (HR 1.011, p = 0.042), contrast enhancement (HR 1.540, p = 0.001), rapid expanding speed (HR 4.525, p < 0.001), location in insular lobe (HR 1.514, p = 0.020), eloquence involved (HR 2.413, p < 0.001) and corpus callosum involved (HR 1.695, p = 0.002) were identified as risk factors of postoperative malignant progression of LGGs. High Karnofsky Performance Status (KPS) score (HR 0.955, p = 0.001), oligodendroglioma (HR 0.603, p < 0.001), oligoastrocytoma (HR 0.693, p = 0.016), isocitrate dehydrogenase (IDH) mutation (HR 0.406, p = 0.004), 1p19q codeletion (HR 0.534, p < 0.001), O6-methylguanine-DNA methyltransferase promoter (MGMTP) methylation (HR 0.539, p = 0.007), resection operation (HR 0.277, p < 0.001) and high extent of resection (EOR) (HR 0.972, p = 0.038) were identified as factors that decreased the risk of postoperative malignant progression of LGGs. This review identified multiple factors associated with the risk of postoperative malignant progression of LGGs, with moderate to high certainty of evidence supporting several key risk and protective factors. Surgeons should be aware of these factors and consider implementing more active treatment and surveillance measures for high-risk patients to improve prognosis.

#3

Investigation of mismatch repair protein expression in glioma.

Annals of diagnostic pathology2026 Feb

Mismatch repair (MMR) proteins are essential for maintaining genomic stability, and their dysfunction contributes to tumorigenesis in several malignancies. However, their role in glioma remains insufficiently defined. This study evaluated MMR protein expression in Tunisian glioma patients and examined its clinicopathological and prognostic significance. Ninety-five glioma samples were retrospectively analyzed. MMR protein expression was assessed by immunohistochemistry on formalin-fixed, paraffin-embedded tissues. Survival outcomes were evaluated using Kaplan-Meier analysis with Log-Rank testing. MMR expression was retained in 65 tumors (68.4 %) and lost in 30 (31.6 %). Loss of MLH1/PMS2 was observed in 16 tumors, MSH2/MSH6 loss in 12, and complete loss of all MMR proteins in two tumors. The distribution of MMR deficiency varied by histological subtype. Among pilocytic astrocytomas, 7 cases exhibited MMR deficiency, predominantly MLH1/PMS2 (n = 5). Two astrocytomas IDH mutant showed either MLH1/PMS2 or MSH2/MSH6 loss. Altered MMR profiles were also identified in oligodendroglioma IDH-mutant, 1p/19q co-deleted (n = 3), oligoastrocytoma NOS (n = 1), and anaplastic oligodendroglioma NOS (n = 1). In glioblastoma, IDH-wildtype, 14 cases showed heterodimer loss (MLH1/PMS2 or MSH2/MSH6), and two tumors demonstrated complete loss of all MMR proteins. Survival analysis revealed a significant prognostic effect exclusively in glioblastomas IDH-wildtype, where MMR deficiency was associated with worse survival (Log-rank test, p < 0.0001). MMR deficiency is relatively frequent in gliomas and carries prognostic significance, particularly in glioblastoma IDH-wildtype. Incorporating MMR status into molecular profiling may enhance risk stratification and inform therapeutic decision-making in glioma management.

#4

Oligodendrogliomas: findings after classifying the same cohort using pre- and post-World Health Organization (WHO) 2021 criteria.

Brain communications2025

The 2021 World Health Organization (WHO) classification includes the presence of isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion for oligodendrogliomas. The objective of this study was to evaluate the impact of the introduction of this classification in a cohort of oligodendrogliomas. A total of 182 cases with an initial diagnosis of oligodendroglioma by histological criteria were identified, including Grades 2 and 3 and oligoastrocytoma (initial cohort). Subsequently, IDH mutation and 1p/19q codeletion were determined and were present in a total of 91 cases (reclassified cohort). The clinical evolution of both cohorts was analyzed. The mean age was 45 years (14-75), 65% were Grade 2 and 22% were oligoastrocytomas. Complete resection was performed in 47% and biopsy in 7%. After surgery, 50% received radiotherapy, 30% chemotherapy and 36% did not receive adjuvant therapy. In the reclassified cohort, there were no statistically significant differences between Grade 2 and Grade 3 oligodendrogliomas, the median overall survival (OS) in Grade 2 was 13.3 years [95% confidence interval (CI) 8.2-18.4] and 12 years in Grade 3 (95% CI 5.6-18.3). However, in the initial cohort, significant differences were found according to tumour grade. Even in cases without adjuvant treatment, the median OS was 12 years. Compared with this data, the median OS for the cohort that did not meet IDH mutation and 1p/19q codeletion criteria was 7.52 years (95% CI 4.67-10.38). Molecular classification allows a more accurate selection of oligodendrogliomas and implies cases with a better prognosis, regardless of the grade and treatment received. These data should be taken into account in clinical practice and clinical trials.

#5

A dual-genotype IDH-mutant infiltrating glioma, a real oligoastrocytoma in cerebral hemisphere.

IBRO neuroscience reports2025 Jun

Since the 5th edition of CNS WHO classification. the categorization of oligoastrocytoma has been discontinued. It is now understood that the majority of tumors previously identified as oligoastrocytomas can be reclassified into either astrocytomas or oligodendrogliomas based on molecular characteristics. In this report, we present a rare case of true oligoastrocytoma characterized by the coexistence of two distinct cell types within a single tumor mass, as evidenced in imaging findings and histological examination. The left frontal infiltrating glioma displayed calcification, and histological analysis revealed two morphologically distinct regions corresponding to oligodendroglioma and astrocytoma. Immunohistochemical and molecular pathology analyses, including IDH1, ATRX, TP53 mutations, H3K27me3 status, Tert promoter mutations, and 1p/19q co-deletion, are consistent with oligodendroglioma and astrocytoma, respectively. Post-surgery, the patient opted against radiotherapy and chemotherapy and showed no signs of recurrence at a 4-month follow-up, but was subsequently lost to follow-up. This case prompts questions about the prognosis and potential grading criteria for true oligoastrocytoma. It underscores the need for further case studies to potentially re-establish it as a distinct tumor type in future CNS WHO classifications.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC103 artigos no totalmostrando 183

2026

Endoscopic Transorbital Approach for Select Recurrent and Newly Diagnosed Anteromedial Temporal Lobe Gliomas.

Journal of neurological surgery. Part B, Skull base
2026

Risk factors for postoperative malignant progression of lower-grade gliomas: a systematic review and meta-analysis.

Surgical oncology
2026

Investigation of mismatch repair protein expression in glioma.

Annals of diagnostic pathology
2025

Revisiting pediatric HGGs and PNETs according to the WHO CNS5 criteria: A clinical and genomic retrospective analysis.

Neuro-oncology advances
2025

Oligodendrogliomas: findings after classifying the same cohort using pre- and post-World Health Organization (WHO) 2021 criteria.

Brain communications
2025

In silico analysis reveals distinct changes in markers of epithelial to mesenchymal transition in glioma subtypes.

Biomolecules &amp; biomedicine
2025

Low-Grade Glioma in the Differential Diagnosis of Limbic Encephalitis.

Cureus
2025

A Patient With Oligoastrocytoma of Suprasellar Cistern Combined With Infantile Uterus.

The Journal of craniofacial surgery
2025

A dual-genotype IDH-mutant infiltrating glioma, a real oligoastrocytoma in cerebral hemisphere.

IBRO neuroscience reports
2025

Oligoastrocytoma: The Vanishing Entity With True Dual Genotype, a Report, its Molecular Profiles and Review of Literature.

International journal of surgical pathology
2025

Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of chemotherapy in newly diagnosed WHO Grade II diffuse glioma in adults: update.

Journal of neuro-oncology
2024

Geriatric grade 2 and 3 gliomas: A national cancer database analysis of demographics, treatment utilization, and survival.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2024

Single-cell transcriptomic analysis identifies downregulated phosphodiesterase 8B as a novel oncogene in IDH-mutant glioma.

Frontiers in immunology
2024

Rare dual-genotype IDH mutant glioma: Review of previously reported cases and two new cases of true "oligoastrocytoma".

Neuropathology : official journal of the Japanese Society of Neuropathology
2024

Genetically Distinct Oligosarcoma Arising from Oligodendroglioma: Systematic Review & Illustrative Case Example.

World neurosurgery
2024

Design, synthesis and anticancer evaluation of novel arylhydrazones of active methylene compounds.

International journal of biological macromolecules
2023

Meningioma and glioma as the first collision brain tumour reported in small animals.

Journal of comparative pathology
2023

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis.

Scientific reports
2023

Machine learning predicts histologic type and grade of canine gliomas based on MRI texture analysis.

Veterinary radiology &amp; ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
2023

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report.

Frontiers in oncology
2023

Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.

The Lancet. Child &amp; adolescent health
2023

Value of quantitative apparent diffusion coefficients in differentiating low-grade gliomas from mixed neuronal-glial tumors.

World neurosurgery: X
2023

Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report.

Brain tumor pathology
2022

Prevalence of seizures in brain tumor: A meta-analysis.

Epilepsy research
2022

True anaplastic oligoastrocytoma with dual genotype: illustrative case.

Journal of neurosurgery. Case lessons
2022

Subtyping and grading of lower-grade gliomas using integrated feature selection and support vector machine.

Briefings in functional genomics
2022

Malignant oligoastrocytoma in the spinal cord of a cat.

The Journal of veterinary medical science
2022

Clinical Profile, Pathology, and Molecular Typing of Gliomas with Oligodendroglial Morphology: A Single Institutional Experience.

Neurology India
2022

Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma.

Translational oncology
2022

FISH analyses for 1p and 19q status on gliomas: Reporting an 8 years' experience from a tertiary care center in the Middle East.

Annals of diagnostic pathology
2021

Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database.

Frontiers in oncology
2021

Clinical and histopathological profile of dysembryoplastic neuroepithelial tumor: An experience from a tertiary care center.

Journal of cancer research and therapeutics
2021

Rapid Spectroscopic Liquid Biopsy for the Universal Detection of Brain Tumours.

Cancers
2021

Palliative endoscopic third ventriculostomy for pediatric primary brain tumors: a single-institution case series.

Journal of neurosurgery. Pediatrics
2021

Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.

World neurosurgery
2021

High IER5 Gene Expression Is Associated With Poor Prognosis in Glioma Patients.

Frontiers in cell and developmental biology
2021

Incremental Utility of Tc-99m Glucohepatonate Single-Photon Emission Computed Tomography over 18F-Flourodeoxyglucose Positron Emission Tomography in Diagnosis of Brain Tumor Recurrence - Old is Gold.

Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
2021

Prognostic Role of EYA4 in Lower Grade Glioma with IDH1 Mutation and 1p19q Co-Deletion.

World neurosurgery
2020

[Diffuse Astrocytoma with Malignant Progression after Long-term Temozolomide Monotherapy:A Case Report].

No shinkei geka. Neurological surgery
2020

Anaplastic oligoastrocytoma with dual genotype: A case report of a rare entity.

Clinical neuropathology
2020

Risk Stratification in Low Grade Glioma: A Single Institutional Experience.

Neurology India
2020

Incidence of Gliomas in Municipalities of Zenica - Doboj Canton in Bosnia and Herzegovina - A 10-Year Study.

Medeniyet medical journal
2020

A dual-genotype oligoastrocytoma with histologic, molecular, radiological and time-course features.

Acta neuropathologica communications
2020

Surgical treatment of low-grade brain tumors associated with epilepsy.

International review of neurobiology
2020

Nuclear H3 K27me3 is retained in both components of dual genotype oligoastrocytoma.

Neuropathology : official journal of the Japanese Society of Neuropathology
2020

Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.

Annals of clinical and translational neurology
2020

Low expression of FOSL1 is associated with favorable prognosis and sensitivity to radiation/pharmaceutical therapy in lower grade glioma.

Neurological research
2020

Pediatric Kidney Transplantation in Perú: A Single-Center Initial Experience.

Transplantation proceedings
2020

Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas.

The Cochrane database of systematic reviews
2020

Acute and chronic hemorrhage from radiation-induced cavernous malformation associated with late-delayed radiation necrosis in long surviving glioma patients: A case report.

Oncology letters
2019

Engrailed 1 overexpression as a potential prognostic marker in Lower Grade Glioma.

PeerJ
2019

Recurrent Glioma With Lineage Conversion From Oligodendroglioma to Astrocytoma in Two Cases.

Frontiers in oncology
2019

The crystal structure of Capicua HMG-box domain complexed with the ETV5-DNA and its implications for Capicua-mediated cancers.

The FEBS journal
2019

Brain cancer survival in Canada 1996-2008: effects of sociodemographic characteristics.

Current oncology (Toronto, Ont.)
2019

The pan-cancer mutational landscape of the PPAR pathway reveals universal patterns of dysregulated metabolism and interactions with tumor immunity and hypoxia.

Annals of the New York Academy of Sciences
2019

Clinical importance of molecular markers of adult diffuse glioma.

Practical neurology
2019

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).

Journal of neuro-oncology
2019

von Willebrand Factor Gene Expression in Primary Lower Grade Glioma: Mutually Co-Occurring Mutations in von Willebrand Factor, ATRX, and TP53.

Brain tumor research and treatment
2019

Incidence trends of adult malignant brain tumors in Finland, 1990-2016.

Acta oncologica (Stockholm, Sweden)
2019

A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma.

Journal of clinical medicine
2019

Neurosurgical Therapy for Status Epilepticus in Oligoastrocytoma Patients.

World neurosurgery
2020

Oligo-astrocytoma in LZTR1-related Noonan syndrome.

European journal of medical genetics
2019

Allergy may confer better survival on patients with gliomas.

Clinical neurology and neurosurgery
2019

Sequencing of Chemotherapy and Radiotherapy for Newly Diagnosed Anaplastic Oligodendroglioma and Oligoastrocytoma.

American journal of clinical oncology
2019

The Applicability of Haarlem Integrated Diagnostic System in Diffuse Glial Tumors and Molecular Methods Affecting Prognosis.

Balkan medical journal
2019

Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60.

Journal of neuro-oncology
2019

Successful treatment of a BRAF V600E-mutant extracranial metastatic anaplastic oligoastrocytoma with vemurafenib and everolimus.

Cancer biology &amp; therapy
2018

Increased HSPG2 expression independently predicts poor survival in patients with oligoastrocytoma and oligodendroglioma.

European review for medical and pharmacological sciences
2019

Comparison of Radiation Therapy Alone and Chemotherapy Alone for Low-Grade Gliomas without Surgical Resection.

World neurosurgery
2018

Possibility of venoarterial extracorporeal membranous oxygenator being a bridging therapy for hemodynamic deterioration of pulmonary tumor thrombotic microangiopathy prior to initiating chemotherapy: A case report.

Medicine
2018

Extracranial metastasis of anaplastic oligoastrocytoma.

Cancer biology &amp; medicine
2018

Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.

Journal of neuro-oncology
2018

Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.

JAMA oncology
2018

Age and surgical outcome of low-grade glioma in Sweden.

Acta neurologica Scandinavica
2018

Symptomatic Remote Cyst after BCNU Wafer Implantation for Malignant Glioma.

Neurologia medico-chirurgica
2018

Multi-institutional study of treatment patterns in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.

Journal of neuro-oncology
2018

Diffuse low-grade glioma mimicking ischaemic infarct: a case report.

The International journal of neuroscience
2018

Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas.

CNS oncology
2018

The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.

Journal of neuro-oncology
2017

Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases.

PloS one
2018

SEOM clinical guideline of diagnosis and management of low-grade glioma (2017).

Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
2018

SEOM clinical guidelines for anaplastic gliomas (2017).

Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
2017

Spinal metastases of two different grade oligodendrogliomas: a case report and review of literature.

Journal of spine surgery (Hong Kong)
2017

2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know.

Radiographics : a review publication of the Radiological Society of North America, Inc
2018

Intraoperative Squash and Touch Preparation Cytology of Brain Lesions Stained with H+E and Diff-Quik™: A 20-Year Retrospective Analysis and Comparative Literature Review.

Acta cytologica
2018

Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach.

Journal of pathology and translational medicine
2017

Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
2018

Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.

Journal of neurosurgery
2018

WHO 2016 Classification of gliomas.

Neuropathology and applied neurobiology
2018

A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up.

Journal of clinical pathology
2017

Extracranial metastasis of anaplastic oligoastrocytoma: a case report and review of the literature.

International journal of clinical and experimental pathology
2017

Rates of Seizure Freedom After Surgical Resection of Diffuse Low-Grade Gliomas.

World neurosurgery
2017

Extent of resection and timing of surgery in adult low grade glioma.

JPMA. The Journal of the Pakistan Medical Association
2017

Multifocal and multicentric low-grade oligoastrocytoma in a young patient.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
2017

Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
2017

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.

Neuro-oncology
2017

Mapping an Extended Neurochemical Profile at 3 and 7 T Using Accelerated High-Resolution Proton Magnetic Resonance Spectroscopic Imaging.

Investigative radiology
2017

Patterns of care and treatment outcomes in older adults with low grade glioma: a 50-year experience.

Journal of neuro-oncology
2017

Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma As a Distinct Entity?

Journal of neuropathology and experimental neurology
2017

Clinical predictors for survival and treatment outcome of high-grade glioma in Prasat Neurological Institute.

Asian journal of neurosurgery
2018

Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide.

American journal of clinical oncology
2017

The usefulness of 18F-fluorocholine PET/CT in the detection of recurrence of central nervous system primary neoplasms.

Revista espanola de medicina nuclear e imagen molecular
2017

Feline glioma: a retrospective study and review of the literature.

Journal of feline medicine and surgery
2017

The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study.

Neuro-oncology
2017

Focal seizure induced by preoperative navigated transcranial magnetic stimulation in a patient with anaplastic oligoastrocytoma.

Brain stimulation
2016

Treatment Strategies for Low-Grade Glioma in Adults.

Journal of oncology practice
2016

Neurosurgery concepts: Key perspectives on intrathecal fluorescein for detecting intraoperative cerebrospinal fluid leak during endoscopic endonasal surgery, spinal intraarterial chemotherapy, oligoastrocytoma classification by in situ molecular genetics, and prenatal myelomeningocele closure and the need for cerebrospinal fluid shunt placement.

Surgical neurology international
2017

Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status.

Journal of neuro-oncology
2017

Personalized anticancer therapy selection using molecular landscape topology and thermodynamics.

Oncotarget
2017

Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up.

Tumori
2016

Stereotactic brachytherapy using iodine 125 seeds for the treatment of primary and recurrent anaplastic glioma WHO° III.

Journal of neuro-oncology
2016

Molecular and histologic characteristics of pseudoprogression in diffuse gliomas.

Journal of neuro-oncology
2016

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

The Lancet. Oncology
2016

Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

The Lancet. Oncology
2016

Unique case of oligoastrocytoma with recurrence and grade progression: Exhibiting differential expression of high mobility group-A1 and human telomerase reverse transcriptase.

World journal of clinical cases
2016

Intraoperative Probe-Based Confocal Laser Endomicroscopy in Surgery and Stereotactic Biopsy of Low-Grade and High-Grade Gliomas: A Feasibility Study in Humans.

Neurosurgery
2016

Genotyping low-grade gliomas among Hispanics.

Neuro-oncology practice
2016

Symptom resolution in infiltrating WHO grade II-IV glioma patients undergoing surgical resection.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2016

A case of medulloblastoma in adult patient affected by anaplastic oligoastrocytoma.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2016

Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation.

Journal of neuro-oncology
2016

Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2015

IDH1 Mutation in Gliomas in Mosul City - Iraq.

Open access Macedonian journal of medical sciences
2017

High-grade glioma with anterior skull base erosion and intranasal extension: case report.

Journal of neurosurgery
2016

Anaplastic astrocytoma and non-1p/19q co-deleted anaplastic oligoastrocytoma: long-term survival, employment, and performance status of survivors.

Neuro-oncology practice
2016

Pre-operative Embolization of Intracranial and Extracranial Tumors: A Review of 37 Cases.

Journal of the Medical Association of Thailand = Chotmaihet thangphaet
2016

Epidermal Growth Factor Receptor and Ki-67 Expression in Canine Gliomas.

Veterinary pathology
2016

[Glioneuronal tumor with neuropil-like island: report of four cases and review of literature].

Zhonghua bing li xue za zhi = Chinese journal of pathology
2016

Primary Spinal Oligoastrocytoma.

The Journal of craniofacial surgery
2016

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.

The New England journal of medicine
2016

18F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report.

Oncology letters
2016

Overview of Transgenic Glioblastoma and Oligoastrocytoma CNS Models and Their Utility in Drug Discovery.

Current protocols in pharmacology
2016

Low-grade and anaplastic oligodendroglioma.

Handbook of clinical neurology
2016

Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas.

Oncotarget
2016

A rare case of oligoastrocytoma with atypical symptoms initially diagnosed as multiple sclerosis: A case report.

Molecular and clinical oncology
2016

Primary spinal cord anaplastic oligoastrocytoma presenting with paraplegia.

The spine journal : official journal of the North American Spine Society
2016

Presence of neural progenitors in spontaneous canine gliomas: A histopathological and immunohistochemical study of 20 cases.

Veterinary journal (London, England : 1997)
2016

Clinicopathological factors predictive of postoperative seizures in patients with gliomas.

Seizure
2016

Epidermal growth factor receptor (EGFR) gene amplification in high-grade gliomas: Western Indian tertiary cancer center experience.

Neurology India
2016

Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.

Journal of clinical pathology
2016

The effect of pregnancy on survival in a low-grade glioma cohort.

Journal of neurosurgery
2016

A case of osteoclast-like giant cell-rich epithelioid glioblastoma with BRAF V600E mutation.

Brain tumor pathology
2015

Primary spinal oligoastrocytoma mimicking longitudinally extensive transverse myelitis.

Multiple sclerosis and related disorders
2015

Oligodendrogliomas: a short history of clinical developments.

CNS oncology
2015

Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?

CNS oncology
2015

The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Journal of neuro-oncology
2015

Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Journal of neuro-oncology
2015

The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.

Journal of neuro-oncology
2015

Genetics and imaging of oligodendroglial tumors.

CNS oncology
2015

The role of surgery in grade II/III oligodendroglial tumors.

CNS oncology
2016

Does morphological assessment have a role in classifying oligoastrocytoma as 'oligodendroglial' versus 'astrocytic'?

Histopathology
2015

Correlation of diffusion tensor and dynamic susceptibility contrast MRI with DNA ploidy and cell cycle analysis of gliomas.

Clinical neurology and neurosurgery
2015

Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study.

European journal of cancer (Oxford, England : 1990)
2015

PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine.

Anticancer research
2015

A multicenter study of anaplastic oligodendroglioma: the Korean Radiation Oncology Group Study 13-12.

Journal of neuro-oncology
2015

Solitary "aggressive" leptomeningeal anaplastic oligoastrocytoma.

Revue neurologique
2015

Stereotactic interstitial brachytherapy for the treatment of oligodendroglial brain tumors.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
2015

Genetic and epigenetic characterization of low-grade gliomas reveals frequent methylation of the MLH3 gene.

Genes, chromosomes &amp; cancer
2015

Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.

Clinical neurology and neurosurgery
2015

Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.

Journal of neurosurgery
2015

Biopsy Proven Tumefactive Multiple Sclerosis with Concomitant Glioma: Case Report and Review of the Literature.

Frontiers in neurology
2015

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

Oncotarget
2015

Hypomethylated Rab27b is a progression-associated prognostic biomarker of glioma regulating MMP-9 to promote invasion.

Oncology reports
2015

Quantitative fluorescence using 5-aminolevulinic acid-induced protoporphyrin IX biomarker as a surgical adjunct in low-grade glioma surgery.

Journal of neurosurgery
2015

Application of technical strategies for surgical management of adult intrinsic pontine gliomas: a retrospective series.

International journal of clinical and experimental medicine
2015

IDH1 and IDH2 mutations in different histologic subtypes and WHO grading gliomas in a sample from Northern Brazil.

Genetics and molecular research : GMR
2015

Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.

Journal of neuro-oncology
2015

Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.

Cancer control : journal of the Moffitt Cancer Center
2016

Combined ATRX/IDH1 immunohistochemistry predicts genotype of oligoastrocytomas.

Histopathology
2015

Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.

Neuropathology : official journal of the Japanese Society of Neuropathology
2015

Oligodendroglioma: pathology, molecular mechanisms and markers.

Acta neuropathologica
2015

Anaplastic glioma: current treatment and management.

Expert review of neurotherapeutics
2015

Radiotherapy and temozolomide for anaplastic astrocytic gliomas.

Journal of neuro-oncology
2015

Opsoclonus-myoclonus syndrome in a patient with an anaplastic oligoastrocytoma.

Journal of neuro-oncology
2015

Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients.

European journal of nuclear medicine and molecular imaging
2015

Dynamic study of methionine positron emission tomography in patients with glioblastoma with oligodendroglial components.

Brain tumor pathology
2015

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience.

Radiology and oncology
2015

Semiological and electroencephalographic features of epilepsy with amygdalar lesion.

Epilepsy research
2015

Astroblastoma: beside being a tumor entity, an occasional phenotype of astrocytic gliomas?

OncoTargets and therapy
2015

Health-related quality of life in stable, long-term survivors of low-grade glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2015

Possible induction of multiple seizure foci due to parietal tumour and anti-NMDAR antibody.

Epileptic disorders : international epilepsy journal with videotape
2015

Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.

International journal of radiation oncology, biology, physics
2014

The impact of adjuvant radiation therapy for high-grade gliomas by histology in the United States population.

International journal of radiation oncology, biology, physics
2015

Anaplastic oligoastrocytoma: is molecular stratification based on 1p/19q status alone appropriate?

Journal of neuro-oncology

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Oligoastrocitoma.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Oligoastrocitoma

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ainda não achamos doenças com sintomas parecidos o suficiente.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Endoscopic Transorbital Approach for Select Recurrent and Newly Diagnosed Anteromedial Temporal Lobe Gliomas.
    Journal of neurological surgery. Part B, Skull base· 2026· PMID 41808971mais citado
  2. Risk factors for postoperative malignant progression of lower-grade gliomas: a systematic review and meta-analysis.
    Surgical oncology· 2026· PMID 41242200mais citado
  3. Investigation of mismatch repair protein expression in glioma.
    Annals of diagnostic pathology· 2026· PMID 41130168mais citado
  4. Oligodendrogliomas: findings after classifying the same cohort using pre- and post-World Health Organization (WHO) 2021 criteria.
    Brain communications· 2025· PMID 40756771mais citado
  5. A dual-genotype IDH-mutant infiltrating glioma, a real oligoastrocytoma in cerebral hemisphere.
    IBRO neuroscience reports· 2025· PMID 40092656mais citado
  6. Revisiting pediatric HGGs and PNETs according to the WHO CNS5 criteria: A clinical and genomic retrospective analysis.
    Neurooncol Adv· 2025· PMID 40980447recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:251656(Orphanet)
  2. MONDO:0016702(MONDO)
  3. GARD:9769(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q1938668(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Oligoastrocitoma
Compêndio · Raras BR

Oligoastrocitoma

ORPHA:251656 · MONDO:0016702
CID-10
C71.9 · Neoplasia maligna do encéfalo, não especificado
CID-11
Ensaios
6 ativos
MedGen
UMLS
C0280793
Repurposing
2 candidatos
carmustineDNA alkylating agent|DNA inhibitor
temozolomideDNA alkylating agent
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades